OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-12-31-accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees David Oxnam (Chair of Board of Trustees) Gayle Routledge Rachel Wilcox David Hobin (Appointed 14 April 2021) Sarah Curtis (Appointed 14 April 2021) Chief Executive Ashley Ball-Gamble Charity number 1182637 (England and Wales) SC049948 (Scotland) Company number CE016951 Operating name CCLG Principal address Century House 24 De Montfort Street Leicester LE1 7GB Auditor Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT Bankers HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

Page
Trustees' report 1 - 10
Independent auditor's report 11 - 13
Statement of financial activities 14
Balance sheet 15
Statement of cash flows 16
Notes to the financial statements 17 - 30

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

The trustees of The Children’s Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2021.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity’s governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (“FRS 102”), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of The Children’s Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

  1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.

  2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.

  3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.

  4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland’s professional association for all those involved in the treatment and care of children with cancer (including leukaemia). Our multidisciplinary and multi-professional membership continues to grow. At the end of 2021, there were in excess of 1000 members. In addition, we host Teenagers and Young Adults with Cancer (TYAC), a multidisciplinary and multi-professional membership association for those involved in the treatment and care of teenagers and young adults with cancer. At the end of 2021, there were more than 400 TYAC members.

Through our membership activities, we provide an active forum for professionals to work together to share best practice and advance education and professional development. Members are able to network with both national and international colleagues for advice and support and receive information and vital updates on specific diseases and treatments. This ensures every child with cancer receives the best possible treatment and care available wherever they live.

The activities of our professional association and membership body include:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

We support children and young people with cancer and their families in a variety of different ways:

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 40 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured.

But there are still some childhood cancers with a poor outlook, and some treatments can have long-lasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments.

We fund and support a variety of research into childhood cancers including:

We measure our success in achieving our objectives in a number of ways:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

ACHIEVEMENTS AND PERFORMANCE

More than 1,800 children and a further 2,300 teenagers and young adults are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements are detailed below.

The global COVID-19 pandemic continued to have an impact on our work during 2021. Many of our usual activities were not able to continue in their usual way, including our face-to-face professional education meeting and events. At the start of the year, the continued impact of restrictions on our fundraising activity was unknown, and so we set a cautious – but optimistic – budget, planning to invest reserves in our activities. In the first half of the year, we continued to use the Government’s Coronavirus Job Retention Scheme to flexibly furlough a number of staff, to help mitigate for a loss in income. We also restructured the staff team during the year, to ensure that as we emerged from the pandemic and associated restrictions, we had the right team in place to return to growing our financial resources and delivering our services. This resulted in some redundancies, as well as the recruitment of some new posts. The Trustees would like to thank the staff team for their continued commitment to CCLG during a difficult time.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland’s professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children’s cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. In 2021:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently. Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2021:

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives.

We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2021:

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer. Our Research Strategy outlines our exciting plans to fund and support innovative world-class research

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements:

Teenagers and Young Adults with Cancer (TYAC)

Teenagers and Young Adults with Cancer (TYAC) is the professional association for those working in teenage and young adult (TYA) oncology. TYAC merged with CCLG in 2018, and in 2019 we launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in TYA cancer care, and support the development of professionals working in the field.

During the year, we launched a new TYAC website, hosting a wide-range of expert cancer information written specifically for young people with cancer. We launched a new research strategy for TYAC, setting out our plans for increasing funding for specialist research into cancer in this age group, and launched our first research grant call, focusing on the late effects of teenage and young adult cancer. We established a Research Advisory Group for TYAC, and committed to developing the research community in this field through the TYAC Research Academy. We successfully held a virtual TYAC education conference, and launched a new small grants programme to support the development of TYAC good practice guidance for professionals working with teenagers and young adults.

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer. In 2021:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

COVID-19

In response to the COVID-19 pandemic, we continued to undertake a number of activities during the year to support the families of children and young people with cancer during the unprecedented circumstances:

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer.

We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials.

Our supporters can sign up to make regular donations, or play our lottery which we launched in 2018.

We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations. Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities. Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2021 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, legacy income, and again income from the Coronavirus Job Retention Scheme. We are grateful to Young Lives vs Cancer and Teenage Cancer Trust for their continued support of TYAC activity.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants.

Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity. As previously mentioned, during the year we carried out a review of our staffing needs, to ensure we had the right team in place to recover from the impact of the COVID-19 pandemic and to achieve our strategic and business goals. This resulted in four redundancies during the year (three voluntary, one compulsory) as well as the creation of a number of new posts. Overall headcount at the end of the year was the same as the end of the previous year.

Despite COVID-19 restrictions remaining in force, in one form or another, for much of the year, we started to see encouraging signs of recovery. Our overall income increased by £1,778,879, compared with the year ending December 2020. We saw an increase in donations and fundraising income during the year, as well as an increase in income from charitable activities, primarily as our research partnership with The Little Princess Trust returned to a pre-pandemic pattern of activity.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. tumour specific donations or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure increased in 2021 by £1,352,392 compared to 2020. The primary reason for the increase was again a return to pre-pandemic pattern of activity for our research partnership activity.

Budgeting for the year was always going to be challenging with the unpredictable nature of the pandemic, changing restrictions, and their impact. The Trustees continued to monitor this on an ongoing basis. We had planned to call on our unrestricted reserves during the year, to enable us to meet our commitments and to cautiously reinvest some of these into our charitable activity, as the unrestricted reserves held at the end of 2021 were over the level required by our reserves policy. We ended the year with an overall surplus of £269,120 but a deficit in unrestricted income/expenditure of £87,145. This deficit is lower than originally budgeted for, reflecting better performance against our budget than anticipated.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic has highlighted the importance of an appropriate reserves policy. Given the ongoing uncertainty around the pandemic and the length of time likely until we recover fully, it is important we continue to hold a level of reserves which can sustain our activity until we have a better picture of what postpandemic fundraising might look like, both in the short- and medium-term. We have plans in place to ensure CCLG is ‘fit for the future’ and our reserves policy will ensure we are able to meet those plans.

At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £400,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs.

Total reserves at 31 December 2021 were £1,923,057 of which £1,331,587 are restricted and £591,470 are unrestricted. As at 31 December 2021 the charity’s free reserves totalled £550,028, which is in excess of the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to continue to reinvest excess reserves into charitable activity, while keeping the reserves policy under review. The trustees consider that this ensures that CCLG is ‘fit for the future’.

Our restricted reserves appear high, at £1,331,587 at the end of 2021. Much of our restricted income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. We are planning to invest a significant amount of restricted reserves into research during 2022.

- The financial impact of the COVID 19 pandemic

As highlighted throughout this report, the COVID-19 pandemic in 2021 continues to have an impact on CCLG, both in our operations and our income generation. Fundraising events that were cancelled in 2020 began to take place again during the year, and overall fundraising activity began to recover, particularly in the latter part of the year. The inability to hold ‘in-person’ meetings and events meant that the majority of our education and scientific meetings and conferences – another key source of income – took place virtually, reducing the income received, although this was mitigated to some extent by a corresponding decrease in the expenditure of holding such events.

We continued to monitor income and expenditure closely during the year. Despite ending the year with a deficit in terms of unrestricted income/expenditure, given the circumstances our income and expenditure performed slightly better than expected.

We have developed a fundraising plan for 2022 which has a combination of in-person and virtual activities, based on our learning and evaluation of our activity over the last two years, and hope to continue to recover during 2022.

As well as focusing on mitigating the impact on the charity as much as possible, to secure the future of our work, The Trustees and the Chief Executive have liaised closely during this year to ensure the wellbeing of staff. We continued to use the government’s Coronavirus Job Retention Scheme (“furlough scheme”), taking the difficult decision to ‘flexibly furlough’ a number of our staff team, to support the costs of employing staff during the crisis. This necessitated focusing our work on the most important projects. Supporting our staff throughout this period has been a key priority for the Trustees and Senior Leadership Team. Our staff team is at the heart of what we do and are passionate about the impact CCLG has on children with cancer and their families. We recognise that our committed staff team also have lives outside of their work for CCLG which will have also been affected. The Trustees and Senior Leadership Team are extremely grateful for the dedication of the team, and how they have adapted to the current situation to ensure our vital work continues.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the uncertainty of the financial impact of the COVID-19 pandemic, no further action has been taken on investments. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries.

As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

The CCLG executive is a committee comprised of elected members of the CCLG professional body, along with the CEO, who have delegated authority from the Trustees for deciding and implementing the strategy of the organisation as it relates to the clinical, research and professional elements of our work.

At the end of 2020, as an AMRC member we participated in their 5-yearly peer review audit, which gave us the opportunity to review our research strategy and associated processes. We concluded that our current research strategy remains appropriate and plan to launch a new research strategy once the ongoing Children’s Cancer Priority Setting Partnership has concluded and published the top ten research priorities in this field.

We plan to continue to develop our range of patient/parent information products in response to demand and specific needs identified by both end-users and professionals. In 2022, we will launch an updated and revised version of our Parents’ Guide, our key publication which is given to all families upon diagnosis, and expand our range of information in different formats, including video content.

We also aim to continue raising awareness of CCLG and its activities, with a view to continuing to increase the income and resources available to us to meet our objectives.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children’s Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity’s governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be the CCLG Treasurer, an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity.

Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

The board of trustees meets quarterly and is supported by staff. Four meetings were held in 2021.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience.

Trustees serving during the year were: David Oxnam Dr Daniel Saunders (resigned 1 December 2021) Gayle Routledge Rachel Wilcox Dr David Hobin (appointed 14 April 2021) Dr Sarah Curtis (appointed 14 April 2021)

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

Key Management Personnel during the year were: Ashley Ball-Gamble (Chief Executive) Gill Smitherman (Head of Fundraising) Claire Shinfield (Head of Engagement) Jeanette Hawkins (Chief Nurse)

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The trustees are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity’s constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

David Oxnam

Chair of the board of trustees

Dated: 17 August 2022

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the ‘charity’) for the year ended 31 December 2021 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 10, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditors/audit-assurance/auditor-s-responsibilities-for-the-audit-of-the-fi/description-of-the-auditor% e2%80%99s-responsibilities-for. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

30 August 2022

Chartered Accountants Statutory Auditor West Walk Building 110 Regent Road Leicester LE1 7LT

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2021

Unrestricted
Restricted
funds
funds
2021
2021
Notes
£
£
Income from:
Donations and legacies
3
689,209
765,446
Charitable activities
4
246,353
3,966,769
Investments
5
1,858
-
Total
937,420
4,732,215
Expenditure on:
Raising funds
6
326,581
480
Charitable activities
7
697,984
4,338,569
Other
11
-
36,901
Total
1,024,565
4,375,950
Net (expenditure)/income for the year/
Net movement in funds
(87,145)
356,265
Reconciliation of funds
Total funds brought forward
678,615
975,322
Total funds carried forward
591,470
1,331,587		 Total
2021
£
1,454,655
4,213,122
1,858
5,669,635
327,061
5,036,553
36,901
5,400,515
269,120
1,653,937
1,923,057		 Total
2020
£
1,301,787
2,586,948
2,021
3,890,756
207,508
3,768,858
71,757
4,048,123
(157,367)
1,811,304
1,653,937

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2021

2021 2020
Notes £ £ £ £
Fixed assets
Tangible assets 14 41,442 41,523
Current assets
Stocks 15 35,426 38,697
Debtors 16 3,769,320 3,105,582
Cash at bank and in hand 4,047,115 3,926,525
7,851,861 7,070,804
Liabilities
Creditors: amounts falling due within one
year 17 (3,395,160) (3,053,855)
Net current assets 4,456,701 4,016,949
Total assets less current liabilities 4,498,143 4,058,472
Creditors: amounts falling due after
more than one year 18 (2,575,086) (2,404,535)
Total net assets 1,923,057 1,653,937
The funds of the charity
Restricted funds 20 1,331,587 975,322
Unrestricted funds 21 591,470 678,615
Total charity funds 1,923,057 1,653,937

The financial statements were approved and authorised for issue by the board of trustees on 17 August 2022 and are signed on its behalf by:

David Oxnam (Chair of Board of Trustees)

Trustee

The notes on pages 17 - 30 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

Note
Cash flows from operating activities
Cash generated from operations
26
Investing activities
Purchase of tangible fixed assets
Investment income received
Net cash (used in)/generated from
investing activities
Net cash used in financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year		 2021
£
£
128,855
(10,123)
1,858
(8,265)
-
120,590
3,926,525
4,047,115		 2020
£
£
1,148,161
-
2,021
2,021
-
1,150,182
2,776,343
3,926,525		 2020
£
£
1,148,161
-
2,021
2,021
-
1,150,182
2,776,343
3,926,525
1,150,182
2,776,343
3,926,525

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (“FRS 102”), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity’s activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

(Continued)

1.10 Financial instruments

Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

3 Income from donations and legacies

Unrestricted
Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2021
2021
2021
2020
2020
£
£
£
£
£
Donations
586,019
578,545
1,164,564
372,572
432,458
Legacies
103,190
150,000
253,190
425,000
-
Government grants
-
36,901
36,901
-
71,757
689,209
765,446
1,454,655
797,572
504,215
Income from charitable activities
Unrestricted Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2021
2021
2021
2020
2020
£
£
£
£
£
Registration fees for meetings
26,772
59,074
85,846
64,709
7,119
Member subscriptions and
publication payments
159,731
-
159,731
159,481
-
Grant income for research and
operations
59,850
3,907,695
3,967,545
60,000
2,295,639
246,353
3,966,769
4,213,122
284,190
2,302,758		 Unrestricted
Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2021
2021
2021
2020
2020
£
£
£
£
£
Donations
586,019
578,545
1,164,564
372,572
432,458
Legacies
103,190
150,000
253,190
425,000
-
Government grants
-
36,901
36,901
-
71,757
689,209
765,446
1,454,655
797,572
504,215
Income from charitable activities
Unrestricted Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2021
2021
2021
2020
2020
£
£
£
£
£
Registration fees for meetings
26,772
59,074
85,846
64,709
7,119
Member subscriptions and
publication payments
159,731
-
159,731
159,481
-
Grant income for research and
operations
59,850
3,907,695
3,967,545
60,000
2,295,639
246,353
3,966,769
4,213,122
284,190
2,302,758		 Total
2020
£
805,030
425,000
71,757
1,301,787
Total
2020
£
71,828
159,481
2,355,639
2,302,758 2,586,948

4 Income from charitable activities

5 Income from investments

Unrestricted
Restricted
funds
funds
2021
2021
£
£
Interest
1,858
-
Expenditure on raising funds
Unrestricted
Restricted
funds
funds
2021
2021
£
£
Costs of raising funds
Fundraising platform fees
18,843
-
Website
5,917
-
Fundraising, marketing
and publicity costs
165,383
480
Support costs (note 10)
136,438
-		 Total
Unrestricted
funds
2021
2020
£
£
1,858
2,021
Total
Unrestricted
funds
2021
2020
£
£
18,843
11,703
5,917
3,792
165,863
59,035
136,438
132,978		 Restricted
funds
2020
£
-
Restricted
funds
2020
£
-
-
-
-		 Total
2020
£
2,021
Total
2020
£
11,703
3,792
59,035
132,978

6 Expenditure on raising funds

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

6 Expenditure on raising funds

(Continued)

326,581
480
7
Expenditure on charitable activities
Activities
undertaken
directly
Note 8
£
Support for research
70,500
Information for patients and families
47,104
Improving treatment and care
69,865
187,469
Unrestricted funds
Restricted funds		 327,061
Grant
funding
Note 9
£
4,267,889
-
-
4,267,889		 207,508
Support
Costs
Note 10
£
142,465
212,453
226,277
581,195		 -
Total
2021
£
4,480,854
259,557
296,142
5,036,553
697,984
4,338,569
5,036,553		 207,508
Total
2020
£
3,200,215
242,727
325,916
3,768,858
703,225
3,065,633
3,768,858

8 Expenditure on activities undertaken directly

Support for
research
Information
for patients
and families
Improving
treatment
and care
£
£
£
Staff costs
51,393
-
-
Other tumour specific expenditure
13,190
-
-
Contact magazine expenses
-
36,825
-
Other publication expenses
-
1,403
-
Website
5,917
8,876
8,876
Cost of meetings
-
-
31,782
Travel expenses
-
-
1,072
Membership support costs
-
-
20,558
Other expenses
-
-
7,577
70,500
47,104
69,865		 Total
2021
£
51,393
13,190
36,825
1,403
23,669
31,782
1,072
20,558
7,577
187,469		 Total
2020
£
17,020
15,729
18,680
12,484
15,169
81,017
4,870
8,919
8,189
182,077

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

9
Expenditure on grant funding
Support for
research
Information
for patients
and families
Improving
treatment
and care
Grants to institutions:
£
£
£
University of Birmingham
496,909
-
-
University of Surrey
-
-
-
Newcastle University
1,326,430
-
-
UCL Institute of Child Health
414,795
-
-
University of Sheffield
-
-
-
University of Nottingham
137,689
-
-
University of Ulster
-
-
-
University of Bristol
206,658
-
-
Great Ormond Street
99,576
-
-
University of Southampton
-
-
-
University of Glasgow
31,793
-
-
University of York
-
-
-
University of Cambridge
251,723
-
-
Institute of Cancer Research
599,310
-
-
University of Leeds
198,979
-
-
University of Manchester
86,108
-
-
University of Portsmouth
-
-
-
University of Oxford
-
-
-
University College Dublin
78,303
-
-
Swansea University
208,533
-
-
University of Bath
104,155
-
-
The Royal Marsden Hospital
15,000
-
-
Blood Cancer UK
11,928
-
-
4,267,889
-
-		 Total
2021
£
496,909
-
1,326,430
414,795
-
137,689
-
206,658
99,576
-
31,793
-
251,723
599,310
198,979
86,108
-
-
78,303
208,533
104,155
15,000
11,928
4,267,889		 Total
2020
£
166,952
9,844
74,582
424,623
206,625
255,841
216,108
-
14,954
245,079
439,610
105,027
136,392
299,236
110,775
-
100,901
219,195
-
-
-
-
-
3,025,744

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

10 Expenditure on support costs

Basis of allocation
Staff costs
1
Depreciation & loss on disposal
1
Occupancy expenses
1
Postage
1
Staff training
1
Professional fees
1 / 2
Redundancy costs
1
Analysed between
Raising funds
Charitable activities		 2021
£
545,405
10,204
95,731
13,621
2,660
35,446
14,566
717,633
136,438
581,195
717,633		 2020
£
505,149
9,627
131,841
12,275
6,000
29,123
-
694,015
132,978
561,037
694,015
1 Support costs, excluding governance costs, have been allocated as follows:
Cost of raising funds
20% (2020 - 20%)
Charitable activities
Support for research
20% (2020 - 20%)
Information for patients and families
30% (2020 - 30%)
Improving treatment and care
30% (2020 - 30%)
2 Professional fees include governance costs of £35,446 (2020 - £29,123). Governance costs have been
allocated as follows:
Charitable activities
Support for research
17% (2020 - 17%)
Information for patients and families
22% (2020 - 22%)
Improving treatment and care
61% (2020 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

11 Other expenditure

Unrestricted Restricted Total Unrestricted Restricted Total
funds funds funds funds
2021 2021 2021 2020 2020 2020
£ £ £ £ £ £
Wages - 36,901 36,901 - 71,757 71,757

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year. No trustees were reimbursed for travel expenses during the year (2020 - 1 trustee was reimbursed for travel expenses of £63).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

13 Employees

The average monthly number of employees during the year was:

2021
Number
Total
18
Employment costs
2021
£
Wages and salaries
530,285
Social security costs
51,546
Other pension costs
51,868
Redundancy costs
14,566
648,265
The number of employees whose annual remuneration was more than £60,000 is as follows:
2021
Number
£80,001 - £90,000
1
14
Tangible fixed assets
Computer
equipment,
furniture
and fixtures
£
Cost
At 1 January 2021
63,202
Additions
10,123
At 31 December 2021
73,325
Depreciation and impairment
At 1 January 2021
21,679
Depreciation charged in the year
10,204
At 31 December 2021
31,883
Carrying amount
At 31 December 2021
41,442
At 31 December 2020
41,523		 2020
Number
18
2020
£
499,229
45,200
49,497
-
593,926
2020
Number
1
Total
£
63,202
10,123
73,325
21,679
10,204
31,883
41,442
41,523

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

15
Stocks
Merchandise stock
Educational literature
16
Debtors
Amounts falling due within one year:
Trade debtors
Grant debtors
Rent deposit
Prepayments and accrued income
Accrued legacy income
Amounts falling due after more than one year:
Grant debtors
Total debtors
17
Creditors: amounts falling due within one year
Trade creditors
Grant creditors
Accruals
18
Creditors: amounts falling due after more than one year
Grant creditors		 2021
£
14,483
20,943
35,426
2021
£
81
2,349,235
16,200
130,113
205,000
2,700,629
2021
£
1,068,691
3,769,320
2021
£
55,830
3,293,878
45,452
3,395,160
2021
£
2,575,086		 2020
£
23,564
15,133
38,697
2020
£
10,152
1,661,876
16,200
140,633
445,000
2,273,861
2020
£
831,721
3,105,582
2020
£
20,902
2,987,921
45,032
3,053,855
2020
£
2,404,535

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised in unrestricted expenditure was £51,868 (2020 - £49,497).

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

Balance at
1 January
2021
£
Tumour specific funds
744,648
CCLG Prize
54
General research fund
3,940
Adam Hay fund
10,982
CCLG Senior Members Group
7
PODC
3,338
POTG
2,139
The Little Princess Trust fund
6,200
Treatment Guidelines fund
18,435
TYAC Lisa Thaxter
45,412
Child Cancer Smart
73,500
PORT
400
CCLG Research Network Partner Charity
36,328
Neuroblastoma Nursing Group
10,500
Childhood Cancer Priority Setting Partnership
17,909
PODC - Iraq Fund
1,530
Coronavirus Job Retention Scheme
-
975,322		 Movement in funds
Income
Expenditure
Balance at
31 December
2021
£
£
£
780,510
(412,585)
1,112,573
-
-
54
-
-
3,940
120
-
11,102
-
-
7
1,444
-
4,782
2,947
(4,876)
210
3,907,695
(3,907,695)
6,200
-
(210)
18,225
-
(1,280)
44,132
-
(633)
72,867
20
-
420
-
6,139
42,467
-
-
10,500
-
(17,909)
-
2,578
-
4,108
36,901
(36,901)
-
4,732,215
(4,375,950)
1,331,587

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

20 Restricted funds

(Continued)

Balance at
1 January
2020
£
Tumour specific funds
930,227
CCLG Prize
304
General research fund
2,982
Adam Hay fund
11,861
CCLG Senior Members Group
7
PODC
3,317
POTG
2,139
The Little Princess Trust fund
6,200
Treatment Guidelines fund
18,661
TYAC Lisa Thaxter
45,412
Child Cancer Smart
174,944
PORT
200
CCLG Research Network Partner Charity
72,656
CYP Coalition Activity
9,034
Neuroblastoma Nursing Group
6,000
Childhood Cancer Priority Setting Partnership
21,580
PODC - Iraq Fund
215
Coronavirus Job Retention Scheme
-
1,305,739		 Movement in funds
Income
Expenditure
Balance at
31 December
2020
£
£
£
425,593
(611,172)
744,648
-
(250)
54
6,387
(5,429)
3,940
120
(999)
10,982
-
-
7
1,462
(1,441)
3,338
-
-
2,139
2,248,667
(2,248,667)
6,200
-
(226)
18,435
-
-
45,412
-
(101,444)
73,500
200
-
400
46,972
(83,300)
36,328
-
(9,034)
-
4,500
-
10,500
-
(3,671)
17,909
1,315
-
1,530
71,757
(71,757)
-
2,806,973
(3,137,390)
975,322

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members’ Group to be used for their activities.

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

20 Restricted funds

(Continued)

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

CYP Coalition Activity

Represents income received from charity members of the Children and Young People's Cancer Coalition for the costs of providing the Coalition secretariat.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

Childhood Cancer Priority Setting Partnership

Represents grant income received to support the James Lind Alliance supported Childhood Cancer Priority Setting Partnership being led by CCLG.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Coronavirus Job Retention Scheme

Represents amounts received from the Government to cover staff costs during the Covid-19 pandemic.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

21 Unrestricted funds

The unrestricted funds of the charity include general funds and designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

Movement in funds
Balance at Income Expenditure Balance at
1 January 31 December
2021 2021
£ £ £ £
General funds 678,615 937,420 (1,024,565) 591,470
Movement in funds
Balance at Income Expenditure Balance at
1 January 31 December
2020 2020
£ £ £ £
General funds 505,565 1,083,783 (910,733) 678,615
Analysis of net assets between funds
Unrestricted
Restricted		 Total
Funds Funds
2021 2021 2021
£ £ £
Fund balances at 31 December 2021 are represented by:
Tangible assets 41,442 - 41,442
Current assets/(liabilities) 550,028 3,906,673 4,456,701
Long term liabilities - (2,575,086) (2,575,086)
591,470 1,331,587 1,923,057
Unrestricted
Restricted		 Total
Funds Funds
2020 2020 2020
£ £ £
Fund balances at 31 December 2020 are represented by:
Tangible assets 41,523 - 41,523
Current assets/(liabilities) 637,092 3,379,857 4,016,949
Long term liabilities - (2,404,535) (2,404,535)
678,615 975,322 1,653,937

22 Analysis of net assets between funds

23 Events after the reporting date

Legacy income amounting to £171,554 was notified after 31 December 2021 and has not been recognised in these accounts. £81,554 has subsequently been received.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Within one year
Between two and five years		 2021
£
27,530
48,177
75,707		 2020
£
27,530
75,707
103,237

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £27,530 (2020 - £27,530).

25 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

2021 2020
£ £
Aggregate compensation 217,459 161,873

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

26
Cash generated from operations
Surplus/(deficit) for the year
Adjustments for:
Investment income recognised in statement of financial activities
Depreciation and impairment of tangible fixed assets
Movements in working capital:
Decrease/(increase) in stocks
(Increase) in debtors
Increase in creditors
(Decrease) in deferred income
Cash generated from operations		 2021
£
269,120
(1,858)
10,204
3,271
(663,738)
511,856
-
128,855		 2020
£
(157,367)
(2,021)
9,627
(8,183)
(323,644)
1,648,844
(19,095)
1,148,161

27 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.